SARS-CoV-2 spike P681R mutation enhances and accelerates viral fusion
暂无分享,去创建一个
H. Nasser | T. Fukuhara | Ryosuke Nomura | S. Nakagawa | K. Shimizu | Kei Sato | Jumpei Ito | A. Takaori-Kondo | T. Irie | T. Sakaguchi | K. Tokunaga | Akatsuki Saito | R. Shimizu | K. Sadamasu | Kotaro Shirakawa | S. Ozono | K. Yoshimura | I. Kimura | Y. Kosugi | Jiaqi Wu | Yasuhiro Kazuma | Yoshihito Horisawa | K. Uriu | Terumasa Ikeda | Ryoko Kawabata | M. Nagashima | I. Yoshida | Hiroyuki Asakura | Yuri L. Tanaka | Erika P. Butlertanaka
[1] C. Swanton,et al. Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination , 2021, The Lancet.
[2] D. Ho,et al. Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization , 2021, Cell Host & Microbe.
[3] H. Jäck,et al. SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies , 2021, Cell.
[4] A. Iafrate,et al. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity , 2021, Cell.
[5] William T. Harvey,et al. Author Correction: Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies , 2021, Nature.
[6] Graham W. Taylor,et al. Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies , 2021, Nature.
[7] D. Ho,et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7 , 2021, Nature.
[8] G. Schreiber,et al. An Emerging SARS-CoV-2 Mutant Evades Cellular Immunity and Increases Infectivity , 2021, SSRN Electronic Journal.
[9] D. Fremont,et al. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies , 2021, Nature Medicine.
[10] Vineet D. Menachery,et al. The variant gambit: COVID-19’s next move , 2021, Cell Host & Microbe.
[11] M. Beer,et al. SARS-CoV-2 spike D614G change enhances replication and transmission , 2021, Nature.
[12] H. Mouquet,et al. Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies , 2021, Nature Medicine.
[13] D. Fremont,et al. Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization , 2021, Cell Host & Microbe.
[14] D. Ho,et al. Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization , 2021, bioRxiv.
[15] Vineet D. Menachery,et al. Loss of furin cleavage site attenuates SARS-CoV-2 pathogenesis , 2021, Nature.
[16] K. Brennand,et al. Fitness selection of hyperfusogenic measles virus F proteins associated with neuropathogenic phenotypes , 2020, Proceedings of the National Academy of Sciences.
[17] W. Kamitani,et al. Establishment of a reverse genetics system for SARS-CoV-2 using circular polymerase extension reaction , 2020, bioRxiv.
[18] M. Beltramello,et al. Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology , 2020, Cell.
[19] Pardis C Sabeti,et al. Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant , 2020, Cell.
[20] D. A. Jackson,et al. Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G on Transmissibility and Pathogenicity , 2020, Cell.
[21] Pardis C Sabeti,et al. Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant , 2020, bioRxiv.
[22] G. Atwal,et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies , 2020, Science.
[23] W. Xu,et al. Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion , 2020, Cell Research.
[24] E. Holmes,et al. A new coronavirus associated with human respiratory disease in China , 2020, Nature.
[25] Kai Zhao,et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin , 2020, Nature.
[26] Olga Chernomor,et al. IQ-TREE 2: New Models and Efficient Methods for Phylogenetic Inference in the Genomic Era , 2019, bioRxiv.
[27] M. Carpenter,et al. HIV-1 restriction by endogenous APOBEC3G in the myeloid cell line THP-1. , 2019, The Journal of general virology.
[28] D. Burton,et al. Recent progress in broadly neutralizing antibodies to HIV , 2018, Nature Immunology.
[29] O. Schwartz,et al. HIV-1 cell-to-cell transmission and broadly neutralizing antibodies , 2018, Retrovirology.
[30] A. Kim. Hepatitis C Virus , 2016, Annals of Internal Medicine.
[31] Satoshi O. Suzuki,et al. Mutant Fusion Proteins with Enhanced Fusion Activity Promote Measles Virus Spread in Human Neuronal Cells and Brains of Suckling Hamsters , 2012, Journal of Virology.
[32] R. Swanstrom,et al. The HIV-1 Env Protein: A Coat of Many Colors , 2012, Current HIV/AIDS Reports.
[33] N. Kondo,et al. Monitoring Viral‐Mediated Membrane Fusion Using Fluorescent Reporter Methods , 2011, Current protocols in cell biology.
[34] Q. Sattentau,et al. Avoiding the void: cell-to-cell spread of human viruses , 2008, Nature Reviews Microbiology.
[35] S. Cocklin,et al. The V1-V3 region of a brain-derived HIV-1 envelope glycoprotein determines macrophage tropism, low CD4 dependence, increased fusogenicity and altered sensitivity to entry inhibitors , 2008, Retrovirology.
[36] T L Hoffman,et al. Stable exposure of the coreceptor-binding site in a CD4-independent HIV-1 envelope protein. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[37] M. Billeter,et al. A matrix‐less measles virus is infectious and elicits extensive cell fusion: consequences for propagation in the brain , 1998, The EMBO journal.
[38] V. Saliba,et al. Public Health in England. , 1988, Public health.